USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novocure GMBH

USPTO PatentsView assignee record — 133 granted patents across 28 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY).

133
Total patents granted
28
CPC technology areas
13.7
Avg claims per patent
+1130%
5-year filing velocity

The verdict

Novocure holds 133 US patents across 28 technology areas — rank #2,882 of 50,000 tracked assignees.

#2,882
of 50,000 US assignees by volume
Top 2%
by Innovation Score (63.9/100)
13.7
avg claims per patent
+1130%
filing velocity, last 5 yrs

Portfolio overview

Novocure GMBH has been granted 133 US utility patents between 2015 and 2025, placing Novocure GMBH at rank #2,882 across all assignees tracked by PlainPatent. This portfolio spans 28 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.7 claims per patent with primary concentration in A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY). As a Foreign Corporation, Novocure GMBH is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 63.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 123 grants, compared with 10 in the 2015–2019 window — a +1130% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Novocure GMBH's 13.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 28 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novocure GMBH against peers pursuing similar technology classes.

How does Novocure compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Novocure holds 133 patents — placing it at rank #2,882 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Novocure's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

64 Top 2% higher than 98% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). Below this entry. 60–70: 1,537 US assignees (3%). This entry sits in this band. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

-1001020304050 20152016201720182019202020212022202320242025 38
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Novocure GMBH patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 4 3.0%
2016 1 0.8%
2017 2 1.5%
2018 1 0.8%
2019 2 1.5%
2020 2 1.5%
2021 10 7.5%
2022 18 13.5%
2023 16 12.0%
2024 39 29.3%
2025 38 28.6%

Which technologies does Novocure GMBH patent most?

Top 15 of 28 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Accelerating

Where it ranks

Overall rank by patents

#2,882

Across all tracked assignees

Innovation Score

63.9 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Novocure GMBH hold?
Novocure GMBH holds 133 US granted patents filed between 2015 and 2025, spanning 28 technology areas.
What is Novocure GMBH's Innovation Score?
Novocure GMBH has an Innovation Score of 63.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Novocure GMBH focus on?
Novocure GMBH's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY) with 101 patents. The company has filed patents in 28 CPC subclasses total.
Is Novocure GMBH's patent filing rate increasing or decreasing?
Novocure GMBH's recent filing velocity is +1130% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Novocure GMBH's patents?
Novocure GMBH's patents average 13.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the Novocure GMBH patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope